Invicta Diagnostic schedules H2 FY26 earnings call on May 23
Invicta Diagnostic Limited will hold a conference call on May 23, 2026, at 12:00 PM IST to discuss its H2 FY26 performance. CFO Rohit Prakash Srivastava will lead the session.

*this image is generated using AI for illustrative purposes only.
Invicta Diagnostic Limited has scheduled an earnings conference call to discuss its financial performance for the half-year ended March 31, 2026. The meeting will take place on May 23, 2026, at 12:00 PM IST, pursuant to Regulation 30(6) read with point 15(a) of Para A Part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Conference Call Details
The conference call is open to investors and analysts. It will provide an overview of the company's operational and financial results for the specified period. Participants are advised to dial in 10 minutes prior to the scheduled start time to ensure a timely connection.
Joining Information
| Access Type | Details |
|---|---|
| Universal Dial In | +91 22 6280 1239, +91 22 7115 8140 |
| Online Registration | Diamond Pass Login Available |
| Date & Time | May 23, 2026, 12:00 PM Onwards |
Management Participation
The discussion will be led by key members of the company's management team. The primary speaker for the session will be Mr. Rohit Prakash Srivastava, who serves as the Chief Financial Officer & Whole Time Director of Invicta Diagnostic Limited .
The company has stated that certain statements made during the call may be forward-looking and subject to risks and uncertainties. Actual results may differ materially from those expressed or implied during the discussion.
Historical Stock Returns for Invicta Diagnostic
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.98% | -25.31% | -17.32% | -30.87% | -30.87% | -30.87% |
How has Invicta Diagnostic Limited's revenue growth trajectory compared to peers in the diagnostic sector over the past few quarters?
What expansion plans or capital allocation strategies might management reveal for the second half of FY2026?
How could rising competition from larger diagnostic chains like Dr. Lal PathLabs or Metropolis impact Invicta's margins going forward?



























